TUMOUR-INFILTRATING LYMPHOCYTES AND INTERLEUKIN-2 IN TREATMENT OF ADVANCED CANCER

Richard L. Kradin; David S. Lazarus; Steven M. Dubinett; Julie Gifford; Beverly Grove; James T. Kurnick; Frederic I. Preffer; Clare E. Pinto; Elise Davidson; Ronald J. Callahan; H. William Strauss

doi:10.1016/S0140-6736(89)91609-7

TUMOUR-INFILTRATING LYMPHOCYTES AND INTERLEUKIN-2 IN TREATMENT OF ADVANCED CANCER

Richard L. Kradin
, David S. Lazarus
, Steven M. Dubinett
, Julie Gifford
, Beverly Grove
, James T. Kurnick
, Frederic I. Preffer
, Clare E. Pinto
, Elise Davidson
, Ronald J. Callahan
, H. William Strauss

Research output: Contribution to journal › Article › peer-review

320 Scopus citations

Abstract

Tumour-infiltating lymphocytes (TIL) were isolated and expanded from small tumour biopsy samples of twenty-eight patients (thirteen with malignant melanoma, seven with renal cell carcinoma, and eight with non-small-cell lung cancer). The patients were treated with autologous expanded TIL (about 10¹⁰) and continuous infusions of recombinant human interleukin-2 (1-3 x 10⁶ U/m² per 24 h). 29% of the patients with renal cell cancer and 23% of those with melanoma achieved objective tumour responses lasting 3-14 months. Toxic side-effects were limited, and no patient required intensive-care monitoring. Adoptive immunotherapy with TIL and interleukin-2 may be an effective systemic approach to the treatment of some patients with malignant melanoma and renal cell carcinoma.

Original language	English
Pages (from-to)	577-580
Number of pages	4
Journal	The Lancet
Volume	333
Issue number	8638
DOIs	https://doi.org/10.1016/S0140-6736(89)91609-7
State	Published - 18 Mar 1989
Externally published	Yes

Access to Document

10.1016/S0140-6736(89)91609-7

Cite this

@article{c51e8c7238f54755ad0123ac05aea1a3,

title = "TUMOUR-INFILTRATING LYMPHOCYTES AND INTERLEUKIN-2 IN TREATMENT OF ADVANCED CANCER",

abstract = "Tumour-infiltating lymphocytes (TIL) were isolated and expanded from small tumour biopsy samples of twenty-eight patients (thirteen with malignant melanoma, seven with renal cell carcinoma, and eight with non-small-cell lung cancer). The patients were treated with autologous expanded TIL (about 1010) and continuous infusions of recombinant human interleukin-2 (1-3 x 106 U/m2 per 24 h). 29\% of the patients with renal cell cancer and 23\% of those with melanoma achieved objective tumour responses lasting 3-14 months. Toxic side-effects were limited, and no patient required intensive-care monitoring. Adoptive immunotherapy with TIL and interleukin-2 may be an effective systemic approach to the treatment of some patients with malignant melanoma and renal cell carcinoma.",

author = "Kradin, \{Richard L.\} and Lazarus, \{David S.\} and Dubinett, \{Steven M.\} and Julie Gifford and Beverly Grove and Kurnick, \{James T.\} and Preffer, \{Frederic I.\} and Pinto, \{Clare E.\} and Elise Davidson and Callahan, \{Ronald J.\} and Strauss, \{H. William\}",

note = "Funding Information: This study was supported by grants from the National Institutes of Health (CA43244, CA44324) and Ortho Pharmaceutical Corporation.",

year = "1989",

month = mar,

day = "18",

doi = "10.1016/S0140-6736(89)91609-7",

language = "English",

volume = "333",

pages = "577--580",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier B.V.",

number = "8638",

}

TY - JOUR

T1 - TUMOUR-INFILTRATING LYMPHOCYTES AND INTERLEUKIN-2 IN TREATMENT OF ADVANCED CANCER

AU - Kradin, Richard L.

AU - Lazarus, David S.

AU - Dubinett, Steven M.

AU - Gifford, Julie

AU - Grove, Beverly

AU - Kurnick, James T.

AU - Preffer, Frederic I.

AU - Pinto, Clare E.

AU - Davidson, Elise

AU - Callahan, Ronald J.

AU - Strauss, H. William

N1 - Funding Information: This study was supported by grants from the National Institutes of Health (CA43244, CA44324) and Ortho Pharmaceutical Corporation.

PY - 1989/3/18

Y1 - 1989/3/18

N2 - Tumour-infiltating lymphocytes (TIL) were isolated and expanded from small tumour biopsy samples of twenty-eight patients (thirteen with malignant melanoma, seven with renal cell carcinoma, and eight with non-small-cell lung cancer). The patients were treated with autologous expanded TIL (about 1010) and continuous infusions of recombinant human interleukin-2 (1-3 x 106 U/m2 per 24 h). 29% of the patients with renal cell cancer and 23% of those with melanoma achieved objective tumour responses lasting 3-14 months. Toxic side-effects were limited, and no patient required intensive-care monitoring. Adoptive immunotherapy with TIL and interleukin-2 may be an effective systemic approach to the treatment of some patients with malignant melanoma and renal cell carcinoma.

AB - Tumour-infiltating lymphocytes (TIL) were isolated and expanded from small tumour biopsy samples of twenty-eight patients (thirteen with malignant melanoma, seven with renal cell carcinoma, and eight with non-small-cell lung cancer). The patients were treated with autologous expanded TIL (about 1010) and continuous infusions of recombinant human interleukin-2 (1-3 x 106 U/m2 per 24 h). 29% of the patients with renal cell cancer and 23% of those with melanoma achieved objective tumour responses lasting 3-14 months. Toxic side-effects were limited, and no patient required intensive-care monitoring. Adoptive immunotherapy with TIL and interleukin-2 may be an effective systemic approach to the treatment of some patients with malignant melanoma and renal cell carcinoma.

UR - https://www.scopus.com/pages/publications/0024510298

U2 - 10.1016/S0140-6736(89)91609-7

DO - 10.1016/S0140-6736(89)91609-7

M3 - Article

C2 - 2564111

AN - SCOPUS:0024510298

SN - 0140-6736

VL - 333

SP - 577

EP - 580

JO - The Lancet

JF - The Lancet

IS - 8638

ER -

TUMOUR-INFILTRATING LYMPHOCYTES AND INTERLEUKIN-2 IN TREATMENT OF ADVANCED CANCER

Abstract

Access to Document

Fingerprint

Cite this